

Delay in Allotment of Securities Under ANREO Offer

Melbourne, Australia – 3 July 2025: Leading digital health company Adherium Limited (ASX: ADR) (the **Company**) refers to its announcement dated 26 June 2025 in relation to the Company's accelerated non-renounceable entitlement offer to Eligible Shareholders to raise up to approximately \$4.492 million.

The Company advises that the allotment and issue of new shares and new options under the Institutional Entitlement Offer, which experienced a slight delay due to a settlement issue with one of the participating overseas investors, has now been resolved. Allotment of the new shares and new options is now scheduled to occur today, 3 July 2025.

There is no change to the remainder of the timetable of the Entitlement Offer. The Company confirms that it will proceed with quotation of the new shares and new options as previously advised.

Unless otherwise defined, all capitalised terms have their meaning as given in the Replacement Prospectus.

- ENDS -

This ASX announcement was approved and authorised for release by the Board.

Investor Enquiries

Adherium Limited
investors@adherium.com

Media Enquiries:

Haley Chartres
HACK Director
haley@hck.digital

About Adherium (ASX: ADR)

Adherium is a provider of integrated digital health solutions and a worldwide leader in connected respiratory medical devices, with more than 180,000 sold globally. Adherium's Hailie® platform solution provides clinicians, healthcare providers and patients access to remotely monitor medication usage parameters and adherence, supporting reimbursement for qualifying patient management. The Hailie® solution includes a suite of integration tools to enable the capture and sharing of health data via mobile and desktop apps, Software Development Kit (SDK) and Application Programming Interface (API) integration tools, and Adherium's own broad range of sensors connected to respiratory medications. Adherium's Hailie® solution is designed to provide visibility to healthcare providers of medication use history to better understand patterns in patient respiratory disease. Learn more at adherium.com